Key facts
- It has raised $21.1M; the latest was Early Stage VC ($7.0M) in Oct 2025.
- Notable investors include Shenzhen Capital Group, ZhenFund, Qianhai FoF, Changzhou Weichi Investment, Sanya Yazhou Bay Science and Technology City Holding Group — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Salus BioMed
- ·The full record, as it builds
Funding rounds
No funding rounds for Salus BioMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Salus BioMed
Provider and developer of deoxyribonucleic acid (DNA) sequencing platform. The company develops high-definition spatial transcriptomics to measure gene activity, enabling users with diagnosis and treatment of diseases.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2020
- Employees
- 150
- Website
- salus-bio.com/
- Ownership
- Privately Held (backing)
Salus BioMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Salus BioMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Salus BioMed in its N-PORT filings yet. We sweep new filings monthly.